P4HTM and breast cancer: PARK7 (OR: 0.83, 95% CI: 0.77-0.90) and EIF2AK3 (OR: 0.82, 95% CI: 0.73-0.91) demonstrated a significant increase in BC risk with evidence of high co-localization (PH4 ≥ 0.7).